摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl N-[(3-bromo-4-hydroxyphenyl)methyl]carbamate | 1313042-26-0

中文名称
——
中文别名
——
英文名称
tert-butyl N-[(3-bromo-4-hydroxyphenyl)methyl]carbamate
英文别名
(3-bromo-4-hydroxy-benzyl )-carbamic acid tert-butyl ester
tert-butyl N-[(3-bromo-4-hydroxyphenyl)methyl]carbamate化学式
CAS
1313042-26-0
化学式
C12H16BrNO3
mdl
——
分子量
302.168
InChiKey
MYAHCPVNDGLDOL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    403.1±35.0 °C(Predicted)
  • 密度:
    1.403±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS<br/>[FR] SPIROPIPÉRIDINE BENZYLAMINESUTILES COMME INHIBITRICES DE LA BÊTA-TRYPTASE
    申请人:SANOFI SA
    公开号:WO2011079103A1
    公开(公告)日:2011-06-30
    The present invention discloses and claims a series of substituted spiropiperidine benzylamines of formula (I) wherein R is as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents for treating joint inflammation, including arthritis, rheumatoid arthritisand other arthritic condition such as rheumatoid spondylitis, gouty arthπtis, traumatic arthritis, rubella arthritis, psoriatic arthritis, osteoarthritis or other chronic inflammatory joint disease, or diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina or other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, macular degeneration, acute macular degeneration, wet macular degeneration, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcers, or a syncytial viral infection.
    本发明公开并声明了一系列式(I)的取代螺环哌啶苄胺化合物,其中R如本文所述。更具体地说,本发明的化合物是β-色胺酶的抑制剂,因此可用作治疗关节炎,包括关节炎、类风湿关节炎和其他关节炎症状,如类风湿脊柱炎、痛风性关节炎、创伤性关节炎、风疹性关节炎、银屑病性关节炎、骨关节炎或其他慢性炎症性关节疾病,或关节软骨破坏疾病、眼结膜炎、春季结膜炎、炎性肠病、哮喘、过敏性鼻炎、间质性肺病、纤维化、硬皮病、肺纤维化、肝硬化、心肌纤维化、神经纤维瘤、肥厚性瘢痕、各种皮肤病症,例如特应性皮炎和银屑病、心肌梗死、中风、心绞痛或动脉粥样硬化斑块破裂的其他后果,以及牙周病、糖尿病视网膜病变、黄斑变性、急性黄斑变性、湿性黄斑变性、肿瘤生长、过敏反应、多发性硬化、消化性溃疡或合胞病毒感染的药物。
  • INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS
    申请人:CHOI-SLEDESKI Yong Mi
    公开号:US20120245161A1
    公开(公告)日:2012-09-27
    The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of the formula wherein R1, R2, R4 and R5 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines.
    本发明披露和声称一系列被取代的indolyl-piperidinyl benzylamines,其化学式为其中R1、R2、R4和R5如本文所述。更具体地说,本发明的化合物是β-tryptase的抑制剂,因此可用作制药剂。此外,本发明还披露了取代的indolyl-piperidinyl benzylamines的制备方法。
  • Adenine derivatives as protein kinase inhibitors
    申请人:B.C.I. PHARMA
    公开号:US11236093B2
    公开(公告)日:2022-02-01
    The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.
    本发明涉及根据通式(Ⅰ)[化合物(C),以下同]的适于用作激酶抑制剂的化合物,或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体,式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法,该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式(I)化合物本身及其作为药物的用途,以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
  • ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    申请人:B.C.I. Pharma
    公开号:EP3452477A1
    公开(公告)日:2019-03-13
  • [EN] INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS<br/>[FR] INDOLYL-PIPÉRIDINYL BENZYLAMINES INHIBITRICES DE LA BÊTA-TRYPTASE
    申请人:SANOFI SA
    公开号:WO2011079102A1
    公开(公告)日:2011-06-30
    The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of formula (I), wherein R1, R2 and R3 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines. In one of the embodiments, there is provided the compounds of formula (I) wherein R3 is (II).
    本发明公开并要求一系列取代的吲哚基-哌啶基苄胺化合物,其公式为(I),其中R1、R2和R3如本文所述。更具体地说,本发明的化合物是β-tryptase的抑制剂,因此可用作药物制剂。此外,本发明还公开了取代的吲哚基-哌啶基苄胺的制备方法。在其中一个实施例中,提供了公式(I)的化合物,其中R3是(II)。
查看更多